MARKET

VXRT

VXRT

Vaxart Inc
NASDAQ
0.7029
-0.0068
-0.96%
Opening 09:55 04/25 EDT
OPEN
0.7000
PREV CLOSE
0.7097
HIGH
0.7240
LOW
0.6900
VOLUME
240.02K
TURNOVER
0
52 WEEK HIGH
1.590
52 WEEK LOW
0.5300
MARKET CAP
122.21M
P/E (TTM)
-1.2345
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VXRT last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at VXRT last week (0408-0412)?
Weekly Report · 04/15 10:02
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Investorplace · 04/09 20:30
Weekly Report: what happened at VXRT last week (0401-0405)?
Weekly Report · 04/08 10:05
Weekly Report: what happened at VXRT last week (0325-0329)?
Weekly Report · 04/01 10:04
Weekly Report: what happened at VXRT last week (0318-0322)?
Weekly Report · 03/25 10:06
Press Release: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to the Company's new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines.
Dow Jones · 03/20 12:00
Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements
Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Vaxart (VXRT) with a price target of $2.00. The company's lead norovirus vaccine candidate is nearing the end of Phase II trials with promising immunogenicity and efficacy data.
TipRanks · 03/20 11:25
More
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Webull offers Vaxart Inc stock information, including NASDAQ: VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.